ePrints

Benefits of rivastigmine on attention in dementia associated with Parkinson disease

Lookup NU author(s): Professor Ian McKeith

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

In a 24-week, randomized, double-blind, placebo-controlled, multicenter study of rivastigmine, 487 patients with dementia associated with Parkinson disease underwent assessment of attention on the Cognitive Drug Research computerized cognitive assessment system before dosing and 16 and 24 weeks later. Significant benefits of rivastigmine over placebo were seen on all aspects of attention assessed: sustained attention, focused attention, consistence of responding, and central processing speed.

Publication metadata

Author(s): Wesnes KA, McKeith I, Edgar C, Emre M, Lane R

Publication type: Article

Publication status: Published

Journal: Neurology

Year: 2005

Volume: 65

Issue: 10

Pages: 1654-1656

ISSN (print): 0028-3878

ISSN (electronic): 1526-632X

Publisher: Lippincott Williams & Wilkins

URL: http://dx.doi.org/10.1212/01.wnl.0000184517.69816.e9

DOI: 10.1212/01.wnl.0000184517.69816.e9

Altmetrics

Share